Oryzon Genomics' Grant

Oryzon Genomics raised a round of funding on May 18, 2015. Investors include Alzheimer's Drug Discovery Foundation.

Oryzon Genomics is a privately held, clinical stage biopharmaceutical company. Its LSD1 program is covered by 18 patent families and has rendered one compound in clinical trials and another one to ent…

Articles about Oryzon Genomics' Grant: